ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Trial status:Recruiting
Trial ID:
PRESERVE-006
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
OncoC4, Inc.
Recruiting
Trial Details
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Medical Condition
Trial Drug
See more
Phase
Phase 1/Phase 2
Type
Interventional
Estimated Enrolment
141
Estimated Trial Date
Dec 2023 - Jun 2026
Trial Participant Requirements
Age
18+ years
Sex
Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
UC Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Status
Recruiting
Location
Rocky Mountain Cancer Centers USOR
Aurora, Colorado, United States, 80012
Status
Recruiting
Location
Moffitt Cancer Cancer
Tampa, Florida, United States, 33612
Status
Recruiting
Location
Emory University Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Status
Recruiting
Location
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21202
Status
Recruiting
Location
Chesapeake Urology Research Associates
Towson, Maryland, United States, 21204
Status
Recruiting